Establishment Labs Hosting Investor Day on June 12
A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at www.establishmentlabs.com. In-person attendance at the event is limited and requires advanced registration. Please email: ir@establishmentlabs.com for further information.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at www.establishmentlabs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611174293/en/
Contacts
Investor/Media Contact: Raj Denhoy415 828-1044rdenhoy@establishmentlabs.com
擷取數據時發生錯誤
登入存取你的投資組合
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Marvell Technology stock soars 10% on Microsoft AI chip prospects
-- Marvell Technology (NASDAQ:MRVL) stock surged 10% Wednesday after Fubon Research analysts highlighted the company's potential significant revenue opportunity from Microsoft's (NASDAQ:MSFT) AI chip initiatives. According to Fubon Research, Microsoft has upgraded specifications for its Maia300 chip, which Marvell is developing, from 3nm with HBM3E to a more advanced 2nm with HBM4. While this has pushed the production timeline from the first quarter of 2026 to the fourth quarter, analysts believe the project represents a substantial opportunity for Marvell. The Maia300 chip is expected to begin production with 300,000-400,000 units in the fourth quarter of 2026, ramping up to 1.2-1.5 million units in 2027. With an estimated average selling price of $8,000 per chip, Fubon projects potential revenue of $2.4 billion in 2026 and $10-12 billion in 2027 from this project alone. Analysts noted that Microsoft appears to be placing "higher expectations on Maia300 by MRVL, rather than Maia200 which is its own solution." This shift comes as Microsoft reportedly faces challenges with its internal chip design capabilities, with Fubon indicating the tech giant is likely to "rely more on MRVL for the current generations." The research also highlighted that Microsoft has increased the planned volume for its Maia200 chip from 40,000-60,000 units to 150,000-200,000 units in 2026, compensating for the delayed Maia300 rollout. Fubon's report suggests Microsoft may be more generous in pricing than Amazon (NASDAQ:AMZN) Web Services, with Maia300's $8,000 ASP substantially higher than AWS Trainium 2's $1,500, despite both projects having similar turnkey margins of 55-60%. Related articles Marvell Technology stock soars 10% on Microsoft AI chip prospects Clients buying into summer rally, bracing for later pullback, says BofA's Hartnett These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, August 5, 2025, to discuss its financial results and corporate update for the quarter ending June 30, 2025. The live and replayed webcast of the call will be available through the company's website at The replay of the call will be available for three months. About Ultragenyx Pharmaceutical is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. For more information on Ultragenyx, please visit the company's website at: Contact Ultragenyx InvestorsJoshua Higair@ MediaJess Rowlands media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
EXCLUSIVE: Vivakor Sheds Water Transport Business To Refocus On Oil, Slashes $59 Million Debt
Vivakor (NASDAQ:VIVK) on Wednesday announced the sale of the non-core business units of Meridian Equipment Leasing, LLC, and Equipment Transport, LLC, subsidiaries of Vivakor Transportation, LLC, an indirect wholly-owned subsidiary of the company. Vivakor Chair and CEO James H. Ballengee said that the net consideration of approximately $11 million and the elimination of approximately $59 million in debt significantly improved the company's credit metrics and strengthened its capital structure. The transaction results in a modest increase in net equity due to the transfer of associated assets, reduces its overall risk profile, and positions it to better focus on core, high-growth opportunities, with minimal impact on EBITDA, he this transaction, Vivakor exits the produced water transportation sector and expects to realize meaningful annualized interest expense savings. The sale enables the company to streamline operations and focus capital and management attention on higher-margin business segments. Ballengee said that strategically, Vivakor refocused its efforts on expanding crude oil transportation, midstream infrastructure, and environmental remediation services, particularly those centered on reuse technologies. He added that this divestiture supports its ongoing objective to raise cash, reduce expenses, and accelerate the transition toward a more streamlined, capital-efficient business model. Meridian Equipment Leasing, LLC, and Equipment Transport, LLC collectively owned and operated a fleet of trucks and trailers dedicated to transporting oilfield-produced water, primarily serving producers in the Permian and Eagle Ford Basins. In June, Vivakor said it is focusing its growth strategy on the Permian and Eagle Ford Basins, aiming to expand its integrated crude oil storage, logistics, and marketing operations. The company owns and operates 10 pipeline injection stations in key areas of the Permian Basin across Texas and New Mexico. These facilities collect crude oil delivered by truck from production wells and transfer it into major interstate pipelines, including Centurion (Lotus), Plains Basin Pipeline (PAA), and the West Texas System (EPD). Price Action: VIVK stock is up by 14.01% at $1.30 premarket at last check on Wednesday. Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article EXCLUSIVE: Vivakor Sheds Water Transport Business To Refocus On Oil, Slashes $59 Million Debt originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
